乳腺癌患者血清和腫瘤組織VEGF表達與臨床預后的關系_《中國普外基礎與臨床雜志》

作者：

敬靜 , 呂青 , 李宏江 , 鄭鴻

四川大學華西醫院普外科（成都610041）;

關鍵詞：

血管內皮細胞生長因子乳腺癌預后

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討乳腺癌患者血清和腫瘤組織中血管內皮細胞生長因子（VEGF）的表達以及與臨床預后的關系。方法　以44例乳腺癌患者、13例乳腺良性疾病患者和40例正常人為研究對象，分別采用酶聯免疫吸附法（ELISA）檢測其血清VEGF水平，采用免疫組化LSAB法檢測其組織中VEGF、雌激素受體（ER）和原癌基因C-erbB-2 蛋白的表達，并分析其與臨床預后因素如淋巴結轉移情況及臨床分期的關系。結果　乳腺癌組血清和組織中VEGF表達水平（113.88 pg/ml，20 723.99 ）均明顯高于乳腺良性疾病組（55.79 pg/ml，3 594.74），P＜0.001，而乳腺良性疾病組與正常對照組（41.30 pg/ml，-）比較差異無統計學意義（P gt;0.05）；且血清和組織中VEGF的表達呈正相關（r=0.48， P＜0.01）。有淋巴結轉移者血清和組織中VEGF 的表達水平（129.60 pg/ml，28 506.82）明顯高于無淋巴結轉移者（80.80 pg/ml，14 656.73）， P＜0.01；血清和組織中VEGF的表達與腫瘤的臨床分期有關（P＜0.01），但與患者年齡和腫瘤大小無關（P gt;0.05）。乳腺癌患者血清和組織中VEGF表達水平與組織中ER表達呈負相關（r=-0.45，P＜0.05），與C-erbB-2表達呈正相關（r=0.48，P＜0.01）。結論　乳腺癌患者血清和腫瘤組織中VEGF表達呈正相關，且與其臨床預后有關，可作為乳腺癌患者預后判斷的重要參考指標之一。

引用本文： 敬靜,呂青,李宏江,鄭鴻. 乳腺癌患者血清和腫瘤組織VEGF表達與臨床預后的關系. 中國普外基礎與臨床雜志, 2006, 13(6): 705-708. doi: 復制

1.	Zhang L, Hannay JA, Liu J, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance [J]. Cancer Res, 2006; 66(17)∶8770.
2.	O’Shaughnessy JA. Molecular signatures predict outcomes of breast cancer [J]. N Engl J Med， 2006; 355(6)∶615.
3.	Nasu R, Kimura H, Akagi K, et al. Blood flow influences vascular growth during tumour angiogenesis [J]. Br J Cancer, 1999; 79(5-6)∶780.
4.	Vicioso L, Gonzalez FJ, Alvarez M, et al. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer [J]. Am J Clin Pathol, 2006; 125(1)∶111.
5.	Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic [J]. Curr Med Chem, 2006; 13(16)∶1845.
6.	王　良, 任國勝, 涂　剛，等. 外源性透明質酸酶對人乳腺癌細胞侵襲力及血管形成能力的影響 [J]. 中國普外基礎與臨床雜志, 2005; 12(3)∶216.
7.	Vermeulen PB, Salven P, Benoy I, et al. Blood platelets and serum VEGF in cancer patients [J]. Br J Cancer, 1999; 79(2)∶370.
8.	Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease [J]. Cancer, 1999; 85(1)∶178.
9.	Chin KF, Greenman J, Gardiner E, et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer [J]. Br J Cancer, 2000; 83(11)∶1425.
10.	Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 1996; 2(5)∶821.
11.	Shih CH, Ozawa S, Ando N, et al. Vascular endothelial gro-wth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus [J]. Clin Cancer Res, 2000; 6(3)∶1161.
12.	Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth [J]. Cancer Res,2001;61(5)∶1786.
13.	Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis [J]. Oncogene, 2000; 19(53)∶6122.
14.	Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins [J]. Environ Health Perspect, 2000; 108 Suppl 5∶785.
15.	Mueller MD, Vigne JL, Minchenko A, et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta [J]. Proc Natl Acad Sci USA, 2000; 97(20)∶10972.
16.	Murphy CE, Carder PJ, Lansdown MR, et al. Steroid hormone receptor expression in male breast cancer [J]. Eur J Surg Oncol, 2006; 32(1)∶44.
17.	Im SA, Kim SB, Lee MH, et al. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase Ⅱ trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor [J]. Oncol Rep, 2005; 14(2)∶481.
18.	Zhao J, Yan F, Ju H, et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer [J]. Cancer Lett, 2004; 204(1)∶87.

1. 　Zhang L, Hannay JA, Liu J, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance [J]. Cancer Res, 2006; 66(17)∶8770.
2. 　O’Shaughnessy JA. Molecular signatures predict outcomes of breast cancer [J]. N Engl J Med， 2006; 355(6)∶615.
3. 　Nasu R, Kimura H, Akagi K, et al. Blood flow influences vascular growth during tumour angiogenesis [J]. Br J Cancer, 1999; 79(5-6)∶780.
4. 　Vicioso L, Gonzalez FJ, Alvarez M, et al. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer [J]. Am J Clin Pathol, 2006; 125(1)∶111.
5. 　Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic [J]. Curr Med Chem, 2006; 13(16)∶1845.
6. 　王　良, 任國勝, 涂　剛，等. 外源性透明質酸酶對人乳腺癌細胞侵襲力及血管形成能力的影響 [J]. 中國普外基礎與臨床雜志, 2005; 12(3)∶216.
7. 　Vermeulen PB, Salven P, Benoy I, et al. Blood platelets and serum VEGF in cancer patients [J]. Br J Cancer, 1999; 79(2)∶370.
8. 　Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease [J]. Cancer, 1999; 85(1)∶178.
9. 　Chin KF, Greenman J, Gardiner E, et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer [J]. Br J Cancer, 2000; 83(11)∶1425.
10. 　Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 1996; 2(5)∶821.
11. 　Shih CH, Ozawa S, Ando N, et al. Vascular endothelial gro-wth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus [J]. Clin Cancer Res, 2000; 6(3)∶1161.
12. 　Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth [J]. Cancer Res,2001;61(5)∶1786.
13. 　Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis [J]. Oncogene, 2000; 19(53)∶6122.
14. 　Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins [J]. Environ Health Perspect, 2000; 108 Suppl 5∶785.
15. 　Mueller MD, Vigne JL, Minchenko A, et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta [J]. Proc Natl Acad Sci USA, 2000; 97(20)∶10972.
16. 　Murphy CE, Carder PJ, Lansdown MR, et al. Steroid hormone receptor expression in male breast cancer [J]. Eur J Surg Oncol, 2006; 32(1)∶44.
17. 　 Im SA, Kim SB, Lee MH, et al. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase Ⅱ trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor [J]. Oncol Rep, 2005; 14(2)∶481.
18. 　Zhao J, Yan F, Ju H, et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer [J]. Cancer Lett, 2004; 204(1)∶87.

《中國普外基礎與臨床雜志》

乳腺癌患者血清和腫瘤組織VEGF表達與臨床預后的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

乳腺癌患者血清和腫瘤組織VEGF表達與臨床預后的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料